Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of SafeTynadol vs Panadol in Healthy Volunteers
NCT05563961Phase 1Recruiting
- Sponsor
- Sinew Pharma
- Start
- Oct 2022
- Primary completion
- Jun 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of SNP-810 in pain and fever, sponsored by Sinew Pharma. Primary endpoint: Alanine Aminotransferase Level at Day 9. Started Oct 2022; status: recruiting.
02
Drugs
SNP-810
03
Conditions
painfever
Beyond the preview
Go deeper on NCT05563961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05563961.